Safety Evaluation of Bifidobacterium lactis BL-99 and Lacticaseibacillus paracasei K56 and ET-22 in vitro and in vivo

Lu, Hongyun; Wen, Zhang; Liu, Wei-Hsien; Sun, Ting; Lou, Hanghang; Wei, Tongbo; Hung, Wei-Lian; Chen, Qihe

doi:10.3389/fmicb.2021.686541

Cited by 23 publications

(13 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B . lactis BL-99 was deposited in the China Common Microbial Culture Collection and Management Center (CGMCC 15650) on April 26, 2018 [ 29 ] and identified by 16S rRNA gene amplified using the universal primers 27F ( ) and 1492R ( ) [ 45 ]. The standard B .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Bifidobacterium lactis BL-99 modulates intestinal inflammation and functions in zebrafish models

Chen

Liu

Dai³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

This study was designed to explore the therapeutics and the mechanisms of a patented and marked gastric acid and intestine juice-resistant probiotics Bifidobacterium lactis BL-99 (B. lactis BL-99) on the intestinal inflammation and functions in the zebrafish models. After feeding for 6 hours, B. lactis BL-99 was fully retained in the larval zebrafish intestinal tract and stayed for over 24 hours. B. lactis BL-99 promoted the intestinal motility and effectively alleviated aluminum sulfate-induced larval zebrafish constipation (p < 0.01). Irregular high glucose diet induced adult zebrafish intestinal functional and metabolic disorders. After fed with B. lactis BL-99, IL-1β gene expression was significantly down-regulated, and IL-10 and IL-12 gene levels were markedly up-regulated in this model (p < 0.05). The intestinal lipase activity was elevated in the adult zebrafish intestinal functional disorder model after B. lactis BL-99 treatment (p < 0.05), but tryptase content had no statistical changes (p > 0.05). B. lactis BL-99 improved the histopathology of the adult zebrafish intestinal inflammation, increased the goblet cell numbers, and up-and-down metabolites were markedly recovered after treatment of B. lactis BL-99 (p < 0.05). These results suggest that B. lactis BL-99 could relieve intestinal inflammation and promote intestinal functions, at least in part, through modulating intestinal and microbial metabolism to maintain intestinal health.

show abstract

Section: Methodsmentioning

confidence: 99%

“…B . lactis BL-99 was confirmed no dose-dependent mortality and toxicity throughout multidose oral toxicity tests in mice and rats and thus generally recognized as safe (GRAS) status as a probiotic [ 29 ]. In vivo experiments in mice showed that B .…”

Section: Introductionmentioning

confidence: 99%

Bifidobacterium lactis BL-99 modulates intestinal inflammation and functions in zebrafish models

Chen

Liu

Dai³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The bacterial reverse mutation assay, developed by Bruce Ames in 1973 [44], was performed for mutagenicity testing of probiotics such as L. rhamnosus, B. adolescentis, L. paracasei, L. mali, and P. acidilactici [45][46][47]. The genotoxicity was conducted by this assay with different doses of W. cibaria JW15 against four mutant S. typhimurium strains (TA98, TA100, TA1535, and TA1537) and a mutant E. coli strain (WP2uvrA), respectively.…”

Section: Bacterial Reverse Mutation Assaymentioning

confidence: 99%

Safety Evaluation of Weissella cibaria JW15 by Phenotypic and Genotypic Property Analysis

et al. 2021

View full text Add to dashboard Cite

Weissella cibaria is one of the bacteria in charge of the initial fermentation of kimchi and has beneficial effects such as immune-modulating, antagonistic, and antioxidant activities. In our study, we aimed to estimate the safety of W. cibaria JW15 for the use of probiotics according to international standards based on phenotypic (antibiotic resistance, hemolysis, and toxic metabolite production) and genotypic analysis (virulence genes including antibiotic resistance genes). The results of the safety assessment on W. cibaria JW15 were as follows; (1) antibiotic resistance genes (ARGs) (kanamycin and vancomycin etc.) were intrinsic characteristics; (2) There were no acquired virulence genes including Cytolysin (cylA), aggregation substance (asa1), Hyaluronidase (hyl), and Gelatinase (gelE); (3) this strain also lacked β-hemolysis and the production of toxic metabolites (D-lactate and bile salt deconjugation). Consequently, W. cibaria JW15 is expected to be applied as a functional food ingredient in the food market.

show abstract

“…In vitro and in vivo experiments showed that BL-99 is a nonpathogenic strain and could be used in the production of functional food. 11 Then, it was con rmed that BL-99 could maintain intestinal health by reducing intestinal in ammation. 12 Moreover, recent studies suggested that BL-99 could utilize fructo-oligosaccharide (FOS) to regulate the composition and structure of gut microbiota in patients with constipation, thus promoting the production of short chain fatty acids (SCFAs).…”

Section: Introductionmentioning

confidence: 99%

Prolonged efficacy of Bifidobacterium lactis in the treatment of functional dyspepsia

Zhang

Zhao

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Current treatment for functional dyspepsia (FD) has limited and unsustainable efficacy. Probiotics have the potential to alleviate FD; However, the underlying mechanism remains unclear. This study aimed to evaluate the effect and mechanism of probiotics in alleviating FD. Methods A randomized, positive-drug and placebo-controlled clinical trial was conducted; 200 FD patients were randomly divided into four groups (placebo, positive control [proton pump inhibitors, PPI] or Bifidobacterium lactis BL-99 [low, high doses]). The clinical response rates in 8-week treatment, 2-week follow-up and 6-week questionnaire survey periods were recorded. Faecal microbiota and metabolites were assessed by metagenomics, un-target and target metabolomics technology. Results The clinical response rate for BL-99_high [43 (95.6%) of 45] group was significantly higher than that for placebo [28 (62.2%) of 45, P = 0.001], BL-99_low [36 (76.6%) of 47, P = 0.019] or positive control group [34 (70.8%) of 48, P = 0.006] after an 8-week treatment. In particular, BL-99_high group was still higher than that for placebo or positive control group after 2-week follow-up and 6-week questionnaire survey periods. Further metagenomic and metabolomics studies found that PPI significantly decreased the gut microbiota diversity, induced the cluster of Escherichia enterotype and decreased butyrate contents. Interestingly, BL-99 converted the gut microbiota enterotype from Bacteroidetes (Alistipes finegoldii, Alistipes shahii) to Firmicutesc (Roseburia intestinalis, Roseburia inulinivorans) and Escherichia enterotype was not clustered after 8-week treatment, which activates carbohydrate esterase activity, and increases faecal and serum butyrate levels. Conclusion BL-99 sustainably alleviated FD symptoms by altering the taxonomic composition and functional potential of the FD microbiome. Trial registration Chictr.org.cn ChiCTR2000041430.

show abstract

Safety Evaluation of Bifidobacterium lactis BL-99 and Lacticaseibacillus paracasei K56 and ET-22 in vitro and in vivo

Cited by 23 publications

References 54 publications

Bifidobacterium lactis BL-99 modulates intestinal inflammation and functions in zebrafish models

Bifidobacterium lactis BL-99 modulates intestinal inflammation and functions in zebrafish models

Safety Evaluation of Weissella cibaria JW15 by Phenotypic and Genotypic Property Analysis

Prolonged efficacy of Bifidobacterium lactis in the treatment of functional dyspepsia

Contact Info

Product

Resources

About